News > MSF: Newer diabetes drugs and insulin pens priced beyond patient reach

MSF: Newer diabetes drugs and insulin pens priced beyond patient reach

New diabetes medicines and insulin pens are priced multiple times higher than the cost of production, says a costing study by Doctors Without Borders/Médecins Sans Frontières (MSF). Alleging “exorbitant corporate profiteering”, MSF called for policymakers, governments and procurers to act on the study findings, which could impact the affordability of diabetes treatments for people in low- and middle-income countries (LMIC), as well, they said.